Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

Recruiting now

Conditions studied: Parkinson Disease

In brief

The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.

Key facts

Study ID

NCT04724941

Run by

University Hospital Schleswig-Holstein

People needed

2000

Starts

2021-06-01

Expected to finish

2027-12-01

Last updated by the study team

2025-09-22

Who can join

Age: 50 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age between 50 and 99

You may not qualify if…

• Presence of clinical PD at the time of study inclusion
• Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
• other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
• in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)

Where it is running

• Department for Neurology, University of Kiel — Kiel, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.